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ABSTRACT  
Background: Olfactory bulb atrophy is associated with cognitive dysfunction 
in Parkinson’s and Alzheimer’s disease, and with major depression. It has 
been suggested that olfactory bulb atrophy or dysfunction is therefore a 
marker of neurodegeneration. Multiple sclerosis (MS) is now also recognised 
as having a significant neurodegenerative component. Thus, the aim of this 
study was to investigate associations between physical and cognitive 
disability, depression, and olfactory bulb volume in MS. 
Methods: In total, 146 patients with MS (mean age 49±10.9, disease duration 
21.4±9.1 years, median Expanded Disability Status Scale (EDSS) 3.0 (range 
0-7.5), 103 relapsing-remitting, 35 secondary-progessive and 8 primary-
progressive multiple sclerosis) underwent a standardised neurological 
examination, comprehensive neuropsychological testing and magnetic 
resonance imaging (MRI); 27 healthy people served as age- and gender 
matched control subjects. The olfactory bulb was semi-automatically 
segmented on high-resolution 3D T1-weighted MRI. 
Results: Mean olfactory bulb volume was lower in MS than controls 
(185.6±40.1 vs. 209.2±59.3; p=0.006; p=0.018 adjusted for intracranial 
volume). Olfactory bulb volume (normalised to intracranial volume) was similar 
across clinical disease subtypes and did not correlate with cognitive 
performance, EDSS scores or total PD/T2 lesion volume. However, in 
progressive MS, the mean olfactory bulb volume correlated with depression 
scores (Spearman’s rho=-0.38, p<0.05) confirmed using a multivariate linear 
regression analysis including cognitive fatigue scores. This association was 
not observed in relapsing-remitting MS.  
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Conclusion: Olfactory bulb volume was lower in MS than healthy controls. It 
does not seem to mirror cognitive impairment in MS, however, it is associated 
with higher depression scores in progressive MS. 
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INTRODUCTION  
Cognitive impairment is common in multiple sclerosis (MS) with prevalence 
estimates ranging from 40% to 70% [1]. It is more frequent and pronounced in 
progressive forms of MS [1], and has a significant impact on quality of life [2]. 
The cognitive domains commonly affected in patients with MS include 
memory, processing speed, executive functioning, and visuospatial abilities 
[3]. In most MS MRI studies, measures of brain atrophy are more closely 
correlated with cognitive impairment than the WM lesion load on PD/T2 
weighted images, suggesting a greater role for neurodegeneration over 
neuroinflammation in MS cognitive deficits [4].  
An interesting feature of quintessentially neurodegenerative diseases is that 
they do not affect all parts of the brain equally, and in some instances 
involvement of the olfactory system may be an early feature. In Alzheimer’s 
disease cognitive impairment is correlated with olfactory dysfunction [5] and in 
Parkinson’s disease olfactory dysfunction may even precede the motor 
symptoms for many years [6].  
Olfactory dysfunction has been described repeatedly in MS, particularly in 
secondary-progressive (SP)MS, and may even mark transition from relapsing-
remitting to SPMS [7]. The mechanism underlying this is not known, but 
pathology in the subventricular germinal zone has been implicated [8]. This 
region plays a major role in the generation of stem cells, many of which 
migrate into the olfactory bulb following the rostral migratory stream [8]. In 
experimental autoimmune encephalomyelitis (an animal model of MS) 
oligodendrogenesis in the subventricular zone is increased, as is migration of 
stem cells into the brain parenchyma [9], however, stem cell migration to the 
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olfactory bulb is reduced, and this is associated with olfactory memory deficits 
in mice [10]. 
There is only one study demonstrating a moderate (Spearman rho coefficient= 
-0.4) correlation between olfactory bulb volume and cognitive dysfunction in 
MS using the Mini Mental Status Examination [11]. However, the Mini Mental 
Status Examination is not particularly sensitive or specific for MS associated 
cognitive impairments and this study excluded patients with significant 
depression (as assessed using the Beck Depression Inventory) but did not 
look for residual effects of lower levels of mood disturbance on Mini Mental 
Status Examination scores [12]. The lifetime risk of major depression in MS 
patients has been estimated to be as high as 50% compared to 10-15% in the 
general population [13] and is itself associated with cognitive impairments [14]. 
 
We sought to investigate systematically the association between olfactory bulb 
volume, neuropsychological impairment and depression in a large MS cohort.  
 
We addressed the following questions:  
 
I. Does olfactory bulb volume differ between patients and healthy control 
subjects and across clinical disease subtypes (relapsing-remitting (RR)MS, 
secondary progressive (SP)MS, primary progressive (PP)MS)? 
 
II. What are the relative strengths of associations of olfactory bulb volume with 
measures of cognitive disability and depression in different subtypes of MS? 
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We hypothesized that the olfactory bulb volume would be significantly lower in 
SPMS than RRMS. Moreover, we hypothesized that the olfactory bulb volume 
would correlate with the neuropsychogical tests and depression scores and 
that these correlations would be stronger in SPMS compared with RRMS. 
To determine if any associations seen between olfactory bulb volume and 
cognitive impairment was specific, or part of a more generalised process, we 
also looked for correlation between olfactory bulb volume, brain volume and 
physical disability. 
 
PATIENTS AND METHODS 
 
Participants 
Participants were recruited from an ongoing prospective, non-interventional 
cohort study on the phenotype-genotype characterisation of MS. Inclusion 
criteria of this study were: age 18-65 years, diagnosis of MS according to the 
McDonald criteria 2001 [15], EDSS 0-7.5 inclusively. Patients had to have 
neuropsychological testing and brain MRI scans performed in a 28-day period. 
In total, 167 MS patients were included in this substudy. Twenty-one patients 
were excluded due to insufficient image quality and, hence, data of 146 MS 
patients were included in this analysis. Medical history and clinical 
examination of the patients were not indicative of diseases of the central 
nervous system other than MS. Concomitant systemic diseases (such as 
hypothyreosis and diabetes mellitus) and drugs which may affect ability to 
smell and olfactory bulb volumes have been documented. MS subtypes were 
classified using the Lublin-Reingold criteria [16]. Twenty-seven age and 
gender-matched healthy subjects served as controls. All participants gave 
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written informed consent, and this study was approved by our local institutional 
ethics committee. 
 
Assessment of cognitive impairment, fatigue and depression 
All patients were assessed for cognitive function, fatigue severity and 
depression. The cognitive test battery included the Paced Auditory Serial 
Addition Test 3 seconds (PASAT) [17] measuring cognitive processing speed 
in the auditory modality, Symbol Digit Modalities Test (SDMT) [18] measuring 
cognitive processing speed in the visual modality, Verbal Fluency Test [19], 
Interference Test for measuring mental flexibility [19], and an Immediate and 
Delayed Recall Test for measuring memory function [19]. The tests are 
described detailed in Table 1. 
 
The results of the neuropsychological tests were transformed into z scores, 
with normative data from literature serving as a reference. A z-score below -
1.5 was considered as an abnormal test result [20]. Patients were considered 
to be cognitively impaired if they failed in two or more tests, a criterion used in 
previous studies [21]. Depressive symptoms were assessed using the German 
version of the Center for Epidemiologic Studies Depression Scale [22]. We 
measured fatigue, a potential co-founder for neuropsychological performance 
and depression [4] using the Fatigue Scale for Motor and Cognitive Functions 
(FSMC) [23]. 
 
MRI acquisition 
Brain MRI was obtained on a 1.5 Tesla system (MAGNETOM Avanto, 
Siemens Medical Solutions, Erlangen, Germany). The mean time difference 
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between the MRI and neuropsychological examination was 1.2 days (range 0-
14 days). None of the patients had a relapse in-between the 
neuropsychological examination and MRI. The MRI protocol included proton 
density (PD)/T2-weighted sequences and spin-echo T1-weighted sequences 
(all acquired 2D in axial plane with 3 mm thick slices). The volumetric 
measures of the olfactory bulb were obtained from 3D T1-weighted 
Magnetisation Prepared Rapid Gradient Echo (MPRAGE) images with the 
following acquisition parameters: repetition time=1.9 sec; echo time=3.5 ms; 
inversion time=1.9 sec; flip angle 7°; isotropic resolution of 1 mm3; acquisition 
time: 7 min; no gap, acquired in sagittal plane. We used coronal 
reconstructions to minimise the impact of partial volume effects as previously 
proposed [24]. 
 
MRI analysis 
MS lesions (T2-weighted hyperintense and T1-weighted hypointense lesions), 
and the olfactory bulb on the MPRAGE scan, were segmented using the semi-
automated thresholding tool in AMIRA (Version 3.1.1., Mercury Computer 
Systems Inc.). The olfactory bulb was segmented between the crista galli and 
the rostrum of the corpus callosum on coronal reconstructions as previously 
described (Figure 1) [5]. Olfactory bulb volumes were obtained by planimetric 
manual contouring (surface in mm2) and subsequent addition of all surfaces 
multiplied by the slice thickness. The intraclass correlation coefficient using 
this method has been previously shown to be >0.9 both for intra- and 
interobserver variation using the same MRI sequences [5]. Olfactory bulb 
segmentation was carried out by TY and OY blinded to the clinical data and 
under the guidance of an expert neuroradiologist. The intra- and interrater 
13 
variability were 0.90 and 0.73 (Cronbach’s alpha), respectively. Olfactory bulb 
volumes as stated below represent the sum of both sides and mean of both 
consecutive measurements. Total intracranial and brain parenchymal volume 
were assessed by using NeuroQuant software package (CorTechs Labs, La 
Jolla/CA), a fully automated brain MRI segmentation software [25]. Brain 
parenchymal fraction was calculated as the ratio of brain parenchymal tissue 
volume to the total intracranial brain volume [26]. All MPRAGE images were 
reviewed for quality blinded to clinical data. The images of every tenth patient 
were re-reviewed by OY for artifacts and segmentation quality.  
 
Statistics 
Demographic data and MRI results are presented as mean ± standard 
deviation. EDSS values are presented as median (range). Inspection of 
clinical, neuropsychological and MRI results revealed evidence for non-
normality for the EDSS, T2 and T1 Lesion volume, disease duration, fatigue 
and depression scores, Immediate and Delayed Recall Test, Verbal Fluency 
Test, SDMT and PASAT (all p<0.05, Shapiro-Wilk Test). Results were 
compared between groups using general linear model or Mann-Whitney U 
Test depending on the normality of the data. Olfactory bulb volume was 
adjusted for total intracranial volume to control for inter-individual variation 
independent of MS disease effects, and compared across the groups using 
general linear model, covarying for age and gender. The correlations between 
olfactory bulb volume and neuropsychological test performance and 
depression scores were calculated using the Pearson’s or Spearman’s 
correlation test depending on normality of the data. Linear regression analysis 
(inclusion model) was performed to analyse the effect of potentially meaningful 
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covariates on the relation between olfactory bulb volume (adjusted to 
intracranial volume) and depression score. The results were confirmed by 
using bootstrap analysis (n=1000). Given the problems associated with 
formally correcting for multiple comparisons [27] we present results flagged 
using conventional (p<0.05) significance threshold.  
We used SPSS (MAC version 21 SPSS, Chicago, IL, USA) for all statistical 
analyses. 
 
RESULTS 
 
In total, 103 RRMS, 35 SPMS, 8 PPMS patients and 27 healthy control 
subjects were included in this study. Their demographics and clinical 
characteristics are given in Table 2. Four patients had a hypothyreosis and 
further two patients diabetes mellitus, all treated for these concomitant 
conditions.  
Drugs used at the time of study assessment are given in Supplemental Table 
1 (online only).  
 
Neuropsychological test performance  
Results of the neuropsychological testing are given in Table 3 and 
supplementary Table 2 (online only). Thirty out of 146 participants (20.5%) 
were cognitively impaired, 45/146 (30.8%) had one abnormal 
neuropsychological test result and 71/146 (48.6%) were cognitively preserved. 
Patients with progressive MS were more likely cognitively impaired than those 
with RRMS (27.9 vs. 17.5%, p<0.01, Chi Square Test). Test performance 
outside the normative range was most frequently observed with the SDMT, 
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being abnormal in 75/146 (51.4%) of the MS cohort, followed by the Delayed 
recall test (n=26), PASAT (n=15), Interference Test (n=11), Immediate Recall 
Test (n=8) and Verbal Fluency Test (n=5). 
 
Depression  
Depression scores were available in 137/146 patients. Patients with  
progressive MS had significantly higher depression scores than patients with  
RRMS (16.4±11.0 vs. 11.5±10.1, p=0.008, Mann-Whitney test). In total,  
27/137 (19.7%) patients had depression scores that exceeded the test  
threshold accepted as marking significant depression; 12 of these 27 patients  
with depressive symptoms had progressive MS and 15 RRMS. Depression  
scores correlated with cognitive fatigue scores (Spearman’s rho=0.637,  
p<0.001), physical fatigue scores (Spearman’s rho=0.524, p<0.001),  
Immediate Recall Test (Spearman’s rho=-0.283; p=0.001), Delayed Recall  
Test (Spearman’s rho=-0.270; p=0.002), Verbal Fluency Test (Spearman’s  
rho=-0.233; p=0.007), PASAT (Spearman’s rho=-0.239; p=0.005), and SDMT  
scores (Spearman’s rho=-0.386; p<0.001). 
 
Fatigue  
Ninety five (65%) of the 146 patients with MS reported cognitive and 111 
(76%) physical fatigue. Both physical and cognitive fatigue scores were higher 
in progressive MS compared with RRMS (p=0.029 cognitive fatigue; p<0.001 
for physical fatigue; Mann-Whitney test). 
 
Olfactory bulb volume 
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Mean olfactory bulb volume was higher in MS than healthy controls 
(209.2±59.3 vs. 185.6±40.1 µl, p=0.006). This was true after adjusting for 
intracranial volume (p=0.018). In all participants, men had higher olfactory bulb 
volumes than women (204.9±52.0 vs. 178.8±37.0 µl, p=0.001). The difference 
was not significant after adjusting for intracranial volume (p>0.05).  
Olfactory bulb volume correlated with intracranial (Pearson’s r=0.354, 
p<0.001) and brain parenchymal volume (Spearman’s rho=0.317, p<0.001).  
In MS, mean olfactory bulb volume was similar values across the clinical 
disease subtypes. This was true after adjusting for intracranial volume 
(general linear model, Table 4). 
Olfactory bulb volume was similar in 104 MS patients who were on disease 
modifying treatments compared with 42 patients without. Olfactory bulb 
volume (both raw and normalised to intracranial volume) did not correlate with 
total T2-weighted hyperintense or T1-weighted hypointense lesion volume. It 
also did not correlate with EDSS scores, fatigue scores, or any of the 
neuropsychological measures and did not differ between those with and 
without cognitive impairment. Olfactory bulb volume did also not correlate with 
depression scores in the total MS group.  
However, in the progressive MS group, patients with depression (n=12) had 
significantly lower olfactory bulb volumes than those without depression (n=29, 
169.17± 41.6 vs. 202.9 ± 44.8 µl, p=0.031, general linear model, Figure 2, 
missing depression score in 2 progressive MS patients).  
This remained lower after adjusting for intracranial volume (normalised 
olfactory bulb volume in progressive MS patients with depression 0.105±0.022 
vs. 0.125±0.027, p=0.027, general linear model).  
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The proportion of patients taking drugs which might influence olfactory bulb 
volumes (see Supplemental Table 1) was similar between progressive MS 
patients with and without depression (72% vs. 60%, p=0.38, Chi Square Test). 
None of the patients in the progressive MS group had hypothyreosis or 
diabetes mellitus. 
Correspondingly, in patients with progressive MS, olfactory bulb volume 
correlated with depression scores (Spearman’s rho=-0.378, p=0.015) also 
after adjusting for intracranial volume (Spearman’s rho=-0.414; p=0.007, 
supplementary Figure 1 [online only]).  
In contrast, brain parenchmyal fraction and intracranial volume did not 
correlate with olfactory bulb volume (both p>0.05). The association between 
normalised olfactory bulb volume and depression scores was confirmed in a 
multivariate linear regression model with depression score as the dependent 
variable and age, gender, disease duration, EDSS score, T1 hypointense 
lesion volume, PD/T2 hyperintense lesion volume. Moreover, the association 
between normalised olfactory bulb volume and depression remained after 
adding cognitive fatigue score as covariate into the model (p=0.025 for 
olfactory bulb volume normalised to intracranial volume, adjusted R 
square=0.151, for the whole model=0.403, supplementary Table 3 [online 
only]). 
 
DISCUSSION 
In the present study, olfactory bulb volume (adjusted to intracranial volume) 
was lower in MS than healthy controls. However, we did not find any 
differences in olfactory bulb volume between patients with RRMS and SPMS 
or PPMS, and cognitive performance did not correlate with olfactory bulb 
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volume in the total cohort. However, patients with progressive MS and 
depressive symptoms had significantly lower olfactory bulb volumes (adjusted 
for intracranial volume) compared with those without depressive symptoms. 
Moreover, there was an inverse correlation between olfactory bulb volume and 
depression scores in the progressive, confirmed by the multivariate analysis 
including cognitive fatigue scores. We did not find this correlation in the RRMS 
group. 
One previous study has investigated the olfactory bulb volume in MS [11].  
The authors included a group of age- and gender matched healthy controls. 
However, a comparison with our results is not possible as MRI results of 
healthy controls were not documented [11].  
In contrast to our study, Göktas et al. described a significant correlation 
between the Mini Mental Status Examination and EDSS scores and olfactory 
bulb volume in 36 MS patients. We did not find such an association, in our 
larger cohort with a comprehensive cognitive battery, which includes a subset 
of those tests recommended by an international consensus committee for the 
use in MS [28]. Different techniques were used to measure the olfactory bulb 
volume, and it is possible that this has contributed, in part, to the discrepant 
results: Göktas et al. identified the olfactory bulb on coronal slices and traced 
consecutive slices until an abrupt decrease of the olfactory bulb area occurred, 
indicating the posterior border of the olfactory bulb [11]; we measured the 
olfactory bulb between the crista galli and on consecutive slices until the first 
appearance of the rostrum of the corpus callosum, which seems to represent a 
more clear-cut landmark [5]. However, there is no study comparing these 
methods, therefore their relative strength and weaknesses when applied in MS 
are unknown. 
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In patients with progressive MS, we found an association between depression 
scores and olfactory bulb volume, a relation that has not been described in MS 
up to now. Göktas et al. excluded patients with the Beck Depression Inventory 
test score of 15 or higher [11]. Our results are in line with a study 
demonstrating significant lower olfactory bulb volumes in non-MS patients with 
major depression [29].  
Interestingly, in our study, in contrast to the olfactory bulb volume, brain 
parenchymal fraction did not correlate with depression scores in the 
progressive MS group suggesting a more specific involvement of olfactory 
networks in the pathophysiology of depression in progressive MS.  
Although we did not assess olfactory bulb function in our study, previous work 
has shown a clear association between olfactory function and olfactory bulb 
volume after head injury or infection [30] and in MS [11].  
Our results would therefore also appear to be concordant with a previous 
study showing a correlation between depressive symptoms and hyposmia in 
MS [31]. 
The mechanism underlying this possible association is unclear. The olfactory 
tracts connecting the olfactory bulb to higher cortical regions are bidirectional, 
and so processes in the entorhinal cortex, amygdala, septal nuclei, pre-
piriform cortex, hippocampus, subiculum, thalamus and frontal cortex may be 
reflected in olfactory bulb neurons [32] and so olfactory bulb volume [33]. 
Many of these regions form the limbic system, and so are linked with 
motivation and emotional processes [34]. However, another model of 
depression postulates a primary role for olfactory bulb dysfunction in 
depression, with reduced olfactory perception leading to amygdala 
disinhibition which in turn alters emotional responses [35]. 
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Limitations 
In addition to those noted above, there are a few other study limitations worth 
mentioning. We assessed depressive symptoms using a standardised and 
widely used scale. However, as a self-reported outcome it is still at least in part 
subjective [36]. The participants included in this study had subjectively no 
olfactory dysfunction; however, there were not examined by an Ear, Nose and 
Throat specialist to exclude potentially confounding conditions that may affect 
olfactory bulb measures. Theoretically, postviral or posttraumatic conditions 
may influence olfactory bulb volume even if olfactory dysfunction has not been 
complained by the participants. Six patients had concomitant conditions which 
are known to be able to affect the ability to smell [37]. However, none of them 
were in the progressive MS group. Moreover, patients took drugs which may 
affect olfactory bulb volume but the proportion of patients taking these drugs 
was similar in progressive MS patients with and without depression. However, 
this does not exclude that drug side effects may have had an influence on the 
study results. Furthermore, the association between olfactory bulb volume and 
depression scores is derived from a subgroup analysis with a higher risk of 
type I error, and as such needs to be replicated in an independent larger 
cohort [38]. 
 
Conclusions 
Although olfactory bulb volume does not seem to mirror cognitive dysfunction 
in MS, our findings suggest an association between olfactory bulb volume and 
depression in progressive MS. 
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